Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

41.95 -0.03 (-0.07%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	976,766
Open	42.32
Bid (Size)	40.00 (200)
Ask (Size)	42.00 (100)
Prev. Close	41.98
Today's Range	41.40 - 42.99
52wk Range	13.69 - 48.40
Shares Outstanding	105,341,296
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗

May 18, 2026

This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.

Via The Motley Fool

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗

May 17, 2026

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.

Via The Motley Fool

Performance

YTD	+76.6%	+76.6%
1 Month	-6.2%	-6.2%
3 Month	+12.7%	+12.7%
6 Month	+47.8%	+47.8%
1 Year	+186.6%	+186.6%

More News

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗

May 17, 2026

Via The Motley Fool

Edgewise Therapeutics (NASDAQ:EWTX) Beats Q1 Estimates as Long-Term Data Strengthens Case for Sevasemten ↗

May 07, 2026

Via Chartmill

Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗

May 17, 2026

Via The Motley Fool

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

May 14, 2026

Via The Motley Fool

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗

May 14, 2026

Via The Motley Fool

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗

May 14, 2026

Via The Motley Fool

Why Edgewise Therapeutics Stock Topped the Market on Tuesday ↗

March 17, 2026

Via The Motley Fool

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗

March 15, 2026

Via The Motley Fool

This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share ↗

March 15, 2026

Via The Motley Fool

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗

February 20, 2026

Via The Motley Fool

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

Via The Motley Fool

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗

February 19, 2026

Via The Motley Fool

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

Via The Motley Fool

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

Via The Motley Fool

BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗

February 19, 2026

Via The Motley Fool

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Via Stocktwits

Why Edgewise Therapeutics Stock Crushed the Market on Monday ↗

February 09, 2026

Via The Motley Fool

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

Via The Motley Fool

Why Edgewise Therapeutics Stock Rocked the Market Today ↗

December 24, 2025

Via The Motley Fool

Let's take a look at the stocks that are in motion in today's session. ↗

December 24, 2025

Via Chartmill

Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout ↗

December 24, 2025

Via Stocktwits

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

Via MarketMinute

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

Via The Motley Fool

Frequently Asked Questions

Is Edgewise Therapeutics, Inc. - Common Stock publicly traded?

Yes, Edgewise Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Edgewise Therapeutics, Inc. - Common Stock trade on?

Edgewise Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Edgewise Therapeutics, Inc. - Common Stock?

The ticker symbol for Edgewise Therapeutics, Inc. - Common Stock is EWTX on the Nasdaq Stock Market

What is the current price of Edgewise Therapeutics, Inc. - Common Stock?

The current price of Edgewise Therapeutics, Inc. - Common Stock is 41.95

When was Edgewise Therapeutics, Inc. - Common Stock last traded?

The last trade of Edgewise Therapeutics, Inc. - Common Stock was at 09/03/26 04:00 PM ET

What is the market capitalization of Edgewise Therapeutics, Inc. - Common Stock?

The market capitalization of Edgewise Therapeutics, Inc. - Common Stock is 4.42B

How many shares of Edgewise Therapeutics, Inc. - Common Stock are outstanding?

Edgewise Therapeutics, Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.